Summary of Avalo Therapeutics FY Conference Call Company Overview - **Company**: Avalo Therapeutics (NasdaqCM:AVTX) - **Focus**: Development of treatments for hidradenitis suppurativa (HS), an inflammatory skin condition Industry Insights - **Market Size**: HS affects over 1% of the U.S. population, indicating a larger market than previously thought, with significant underdiagnosis and undertreatment [3] - **Current Treatments**: There are three approved compounds for HS, generating aggregate sales in the multiple billions of dollars, with rapid growth expected [3] Product Development - **Product**: AVTX-009, an anti-IL-1 monoclonal antibody - **Clinical Trials**: Top-line Phase II results expected in Q2 2026 [4] - **Mechanism of Action**: IL-1 is a central target in the inflammatory process of HS, driving neutrophil activity and lesion formation [6][7] - **Unique Properties**: AVTX-009 has high affinity and specificity for IL-1, allowing better penetration into lesions, which are under high pressure [8][9] Clinical Trial Design - **Primary Endpoint**: HiSCR75, which measures a 75% reduction in abscess or inflammatory nodule count, is considered more clinically relevant than HiSCR50 [10][11] - **Placebo Response Management**: The trial design includes a large sample size of over 250 patients and collaboration with experienced investigators to mitigate placebo effects [14][15][16] Regulatory Strategy - **Phase III Design**: Plans to discuss with the FDA for potential efficiencies in trial design, considering recent guidance for single pivotal trials [17][18][19] Competitive Landscape - **Market Dynamics**: The HS market is evolving with new entrants and therapies, creating opportunities for differentiation based on mechanism of action, dosing convenience, and safety profile [20][21] - **Strategic Directions**: Focus on the U.S. market initially, with potential for international partnerships and expansion into other therapeutic areas [23] Financial Position - **Cash Reserves**: Approximately $95 million in cash, sufficient to fund operations through the upcoming data release, with plans to raise additional funds for Phase III trials [32] Future Outlook - **Upcoming Milestones**: Anticipation of top-line data from the LOTUS trial next quarter, with potential regulatory discussions for Phase III trials in 2027 [27][29]

Financial Data and Key Metrics Changes - ARCALYST product revenue grew 65% year-over-year to $202.1 million in Q4 2025, and 62% to $677.6 million for the full year 2025 [5][17] - Net income was $14.2 million in Q4 2025, compared to a net loss of $8.9 million in Q4 2024, and net income for the full year 2025 was $59 million, compared to a net loss of $43.2 million for the full year 2024 [17][18] - Cash at the end of 2025 was $414.1 million, representing $170.4 million of net cash generation for the year [19] Business Line Data and Key Metrics Changes - The primary driver of revenue growth was the expanding adoption of interleukin-1 alpha and beta inhibition with ARCALYST as a second-line treatment [9] - The average total duration of therapy for ARCALYST is approaching three years, with robust payer approval rates and strong patient adherence [12] Market Data and Key Metrics Changes - At the end of 2025, ARCALYST had over 4,150 prescribers, with around 29% prescribing for two or more recurrent pericarditis patients [11] - Penetration into the two-plus recurrence target market increased to approximately 18% at the end of 2025, compared to around 15% in mid-2025 and 13% at the end of 2024 [13] Company Strategy and Development Direction - The company aims to unlock the next phase of growth for ARCALYST by driving further physician awareness and advancing digital marketing initiatives [11] - KPL-387 is expected to address key patient needs and expand market penetration by potentially enabling monthly dosing with an auto-injector [7][54] - The company is focused on both ARCALYST and advancing its clinical portfolio to bring additional therapies to patients suffering from debilitating diseases [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of ARCALYST and the potential for KPL-387 to capture additional market share [5][9] - The company is optimistic about the future, emphasizing the importance of ongoing investments in R&D and commercialization efforts [6][20] Other Important Information - The company reported that ARCALYST revenue growth has been profitable since Q4 2021, allowing for strategic investments in sales and marketing [6] - The company expects to remain cash flow positive on an annual basis under its current operating plan [19] Q&A Session Summary Question: What do you think the peak penetration is for ARCALYST in the multiple recurrent setting? - Management has not commented on peak penetration but believes there is significant growth potential remaining [23] Question: Is the pace of growth in first recurrence versus multiple recurrence patients the same? - The percentage of first recurrence patients has grown, and management views this as a positive change as physicians become more comfortable prescribing ARCALYST [29] Question: What is the extent of FDA interactions for KPL-387? - The company values its interactions with the FDA and has laid out a comprehensive development program for KPL-387 [38] Question: Are there differences in persistence rates between first recurrence and multiple recurrence populations? - No meaningful differences in persistence rates have been observed between the two populations [40] Question: How are you thinking about the enrollment curve for the phase III study of KPL-387? - Data from the Phase II portion of the trial is expected in the second half of 2026, with plans for a phase III study thereafter [46]

Summary of Avalo Therapeutics Conference Call Company Overview - **Company**: Avalo Therapeutics (NasdaqCM: AVTX) - **Location**: Based outside of Philadelphia - **Employee Count**: Approximately 35 employees - **Key Asset**: AVTX-009, a fully human anti-IL-1 monoclonal antibody in phase 2b for hidradenitis suppurativa (HS) [2][12] Industry Insights - **Target Mechanism**: IL-1 plays a central role in inflammation, particularly in HS, bridging the innate and adaptive immune responses [4][6] - **Clinical Landscape**: The market for HS treatments is competitive, with a significant need for new mechanisms of action. IL-1 is identified as a top target by dermatologists [35][41] Key Clinical Data - **Lutikizumab Data**: AbbVie’s Lutikizumab showed a 46% crude treatment effect in HS patients, with a placebo-subtracted effect of about 25% [12][13] - **Comparative Advantage**: Avalo believes AVTX-009 has higher affinity and better pharmacokinetics than Lutikizumab, potentially leading to superior efficacy [13][84] Trial Design and Expectations - **Phase 2 Trial**: Completed enrollment with over 250 patients; designed as a 16-week study with a 6-week safety follow-up [56][60] - **Endpoints**: Primary endpoint is HiSCR75, with secondary endpoints including HiSCR50, 90, and 100, as well as quality of life measures [56][58] - **Patient Demographics**: Average of eight years of disease duration, with a mix of early stage 2 and early stage 3 patients [60][62] Future Directions - **Indication Expansion**: Plans to focus on diseases driven by IL-1, including inflammatory bowel disease (IBD), rheumatology, and dermatology [144][150] - **Cash Position**: Avalo has $110 million remaining, expected to last through 2028, with plans to raise additional funds for phase 3 trials [156][158] Additional Considerations - **Antibiotic Use in Trials**: Patients on stable doses of antibiotics are allowed in the study, capped at 20%, with no expected impact on results [135][141] - **Operational Strategy**: Emphasis on solid trial design and conservative estimates for placebo and drug effect sizes to maximize the difference in outcomes [100][111] This summary encapsulates the key points discussed during the conference call, highlighting Avalo Therapeutics' strategic focus, clinical data, and future plans in the context of the competitive landscape for HS treatments.

Financial Data and Key Metrics Changes - ARCALYST revenue grew to $180.9 million in Q3 2025, representing a 61% year-over-year increase and a $24 million increase from the previous quarter [7][17] - Net income for Q3 2025 was $18.4 million, compared to a net loss of $12.7 million in the same quarter last year [17] - Operating expenses increased by 29% year-over-year to $156.8 million, primarily due to collaboration expenses related to ARCALYST [17] Business Line Data and Key Metrics Changes - The adoption of IL-1 inhibition with ARCALYST has driven significant revenue growth, with a 118% year-over-year increase in ARCALYST collaboration profit to $126.6 million [17] - The average duration of therapy for patients on ARCALYST increased to approximately 32 months, indicating higher patient satisfaction and retention [10][25] Market Data and Key Metrics Changes - The company reported that approximately 20% of ARCALYST prescriptions were written for patients following their first recurrence, indicating a shift in treatment patterns [7] - The total prescriber count for ARCALYST reached over 3,825, with more than 350 new prescribers added in Q3 2025 [10][48] Company Strategy and Development Direction - The company aims to maintain its market leadership in recurrent pericarditis through the continued growth of ARCALYST and the development of KPL-387, which has received orphan drug designation from the FDA [6][14] - The strategic focus includes evolving the treatment landscape for recurrent pericarditis and increasing education among healthcare professionals [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of ARCALYST, raising full-year net sales guidance to between $670 million and $675 million [5][12] - The management highlighted the importance of the recent ACC guidelines in promoting IL-1 pathway inhibition as a new standard of care, which is expected to further drive adoption [29][31] Other Important Information - The company maintained a strong cash position, with a cash balance of approximately $352.1 million, increasing by about $44 million in Q3 2025 [17] - The phase 2 dose-focusing portion of the KPL-387 trial is on track to report data in the second half of 2026 [16] Q&A Session Summary Question: Feedback on ARCALYST duration increase - Management noted positive feedback from both patients and healthcare professionals regarding the increased duration of therapy, with a significant reduction in event rates post-treatment [22][25] Question: Incorporation of updated ACC guidelines - The updated guidelines affirm the positioning of IL-1 pathway inhibition as a second-line treatment, which has been integrated into promotional efforts [28][30] Question: Growth dynamics for ARCALYST - The growth dynamics were attributed to increased prescriber confidence and awareness, aided by the ACC guidelines [41][48] Question: Drivers for KPL-387 phase 3 decision - The phase 2 study is designed to confirm the efficacy of the 300 mg subcutaneous dose, which is expected to be the primary focus for the phase 3 trial [42] Question: Increase in prescribers - The increase in prescribers was driven by greater confidence in ARCALYST as a treatment choice and targeted marketing efforts [46][50]